Get the Daily Brief
Latest Biotech News
MoonLake posts mid‑stage win, says FDA filing confidence growing
MoonLake Immunotherapeutics disclosed Phase 2 data showing a clinically meaningful benefit in patients with an aggressive inflammatory arthritis and told Endpoints News it has confidence ahead of...
First‑in‑human nerve‑visualization agent shows rapid, sustained imaging
Illuminare Biotechnologies reported Phase 1 human data for Illuminare‑1, a fluorescent imaging agent that binds myelin to delineate peripheral nerves under blue light. The trial demonstrated rapid...
Lipid nanoparticles: a little disorder improves delivery – new data
Two complementary reports show that internally disordered lipid nanoparticles (LNPs) can deliver RNA cargo more efficiently than highly ordered particles. University of Copenhagen researchers...
Isomorphic’s IsoDDE wows scientists – AI drug engine kept closed
Isomorphic Labs, the DeepMind drug‑discovery spin‑off, released a technical report on IsoDDE—an AI model capable of detailed protein–drug interaction and antibody structure predictions—and kept...
Electrical probes bring organoids closer to predictive drug screens
Diagnostic Biochips announced a neural probe technology for functional electrophysiology in organoid screening that promises higher predictive validity in early‑stage drug testing. Company...
GWAS expansion links 140 loci to age‑related hearing loss
A multi‑ancestry genome‑wide association study led by Shi, He, Li, and colleagues identified 140 genetic loci associated with age‑related hearing loss and published the results in Nature...
Intestinal IL‑22 increases GLP‑1: a new metabolic lever in mice
Researchers reported in Nature Communications that intestinal interleukin‑22 (IL‑22) elevates GLP‑1 production and improves glucose homeostasis in male mice, linking mucosal immunity to metabolic...
Pulsed lasers may sharpen cryo‑ET — sub‑picosecond timing for clearer images
Scientists at Columbia’s Zuckerman Institute and the Maxson lab at Cornell described a laser‑based approach that could enhance cryo‑electron tomography (cryo‑ET) image quality by improving...
Moderna wins FDA reprieve — agency agrees to review mRNA‑1010
The FDA reversed an earlier refusal-to-file and agreed to review Moderna’s seasonal mRNA flu vaccine application, setting a PDUFA target date of Aug. 5. The company proposed an age‑stratified...
DeepMind spin‑off keeps next‑gen drug AI under wraps — scientists stunned
Isomorphic Labs released a technical report touting IsoDDE, a drug‑discovery model its scientists say advances prediction of protein–drug interactions and antibody structures, but the company is...
Korsana pulls in $175M to advance BBB‑crossing Alzheimer’s drug
Korsana Biosciences announced a $175 million financing to accelerate its preclinical Alzheimer’s program built on a platform that shuttles antibodies across the blood–brain barrier. The company...
MoonLake reports mid‑stage win — confidence ahead of FDA submission
MoonLake Immunotherapeutics disclosed Phase 2 data showing a clinically meaningful benefit for its sole investigational drug in an aggressive inflammatory arthritis subtype, and said the results...
Disordered lipid nanoparticles deliver better — studies challenge packing dogma
Two recent reports presented new evidence that lipid nanoparticles (LNPs) with internal disorder release therapeutic cargo more effectively than highly organized particles. Researchers at the...
Focused ultrasound opens BBB via tight‑junction reorganization
Researchers published mechanistic data showing focused ultrasound transiently and reversibly opens the blood–brain barrier by reorganizing tight junction proteins. The study, in Communications...
Illuminare‑1 lights nerves in humans — Phase 1 shows rapid visualization
Illuminare Biotechnologies reported first‑in‑human Phase 1 data for Illuminare‑1, a fluorescent imaging agent that binds myelin and enables surgeons to visualize nerves under blue light....
FDA clears Vanda’s Bysanti — new label for schizophrenia and bipolar I episodes
The FDA approved Vanda Pharmaceuticals’ Bysanti for schizophrenia and for acute manic or mixed episodes of bipolar I disorder. Bysanti is the active metabolite of an existing atypical...
Led by Giroir: Altesa raises $75M to advance antiviral programs
BioCentury reported that Altesa closed a $75 million Series B to advance an antiviral program, with former HHS official Admiral Brett Giroir among the financing backers or leaders named in the...
GRAPE‑LM yields RNA aptamers in a single round — faster evolution for therapeutics
Researchers introduced GRAPE‑LM, a method that enables single‑round directed evolution of RNA aptamers, streamlining what traditionally required multiple cycles of mutation and selection. The...
Grail’s Galleri stumbles: NHS trial misses primary endpoint, shares plunge
Grail’s large NHS-Galleri randomized trial failed to show a statistically significant reduction in late-stage (stage III–IV) cancer diagnoses, the company reported in top-line results. The study...
FDA reverses course on Moderna flu shot – agency sets PDUFA date
The FDA agreed to review Moderna’s mRNA‑1010 seasonal flu vaccine after a Type A meeting, setting an Aug. 5 PDUFA target date and accepting a revised regulatory pathway that seeks full approval in...